Onconetix Ownership
| ONCO Stock | USD 1.09 0.04 3.54% |
Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.
Onconetix |
Onconetix Stock Ownership Analysis
About 58.0% of the company outstanding shares are owned by corporate insiders. The company has price-to-book ratio of 0.31. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Onconetix recorded a loss per share of 109.2. The entity had not issued any dividends in recent years. The firm had 1:40 split on the 24th of September 2024. Oncology Med, Inc. offer full service cancer center solutions. To find out more about Onconetix contact the company at 513 620 4101 or learn more at https://onconetix.gcs-web.com.Besides selling stocks to institutional investors, Onconetix also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different Onconetix's stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align Onconetix's strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.
Onconetix Quarterly Liabilities And Stockholders Equity |
|
About 58.0% of Onconetix are currently held by insiders. Unlike Onconetix's institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against Onconetix's private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of Onconetix's insider trades
Onconetix Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Onconetix insiders, such as employees or executives, is commonly permitted as long as it does not rely on Onconetix's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Onconetix insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Altos Venture Ag 19 hours ago Insider Trading | ||
Altos Venture Ag a day ago Insider Trading | ||
Altos Venture Ag 2 days ago Insider Trading | ||
Altos Venture Ag 3 days ago Insider Trading | ||
Altos Venture Ag few days ago Insider Trading | ||
Altos Venture Ag few days ago Insider Trading | ||
Altos Venture Ag few days ago Insider Trading | ||
Altos Venture Ag six days ago Insider Trading | ||
Altos Venture Ag over a week ago Insider Trading | ||
Altos Venture Ag over a week ago Insider Trading | ||
Altos Venture Ag over a week ago Insider Trading | ||
Altos Venture Ag over a week ago Insider Trading |
Pair Trading with Onconetix
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Onconetix position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Onconetix will appreciate offsetting losses from the drop in the long position's value.Moving together with Onconetix Stock
| 0.62 | A | Agilent Technologies Earnings Call This Week | PairCorr |
| 0.68 | ME | 23Andme Holding | PairCorr |
| 0.74 | VALN | Valneva SE ADR | PairCorr |
| 0.77 | JNJ | Johnson Johnson Sell-off Trend | PairCorr |
Moving against Onconetix Stock
| 0.68 | MDGL | Madrigal Pharmaceuticals | PairCorr |
| 0.55 | RNXT | RenovoRx | PairCorr |
| 0.36 | NXGLW | NexGel Warrant | PairCorr |
| 0.34 | KEP | Korea Electric Power | PairCorr |
The ability to find closely correlated positions to Onconetix could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Onconetix when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Onconetix - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Onconetix to buy it.
The correlation of Onconetix is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Onconetix moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Onconetix moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Onconetix can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Onconetix. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators. To learn how to invest in Onconetix Stock, please use our How to Invest in Onconetix guide.You can also try the Theme Ratings module to determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Onconetix. If investors know Onconetix will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Onconetix listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (109.20) | Revenue Per Share 2.892 | Return On Assets (0.22) | Return On Equity (17.58) |
The market value of Onconetix is measured differently than its book value, which is the value of Onconetix that is recorded on the company's balance sheet. Investors also form their own opinion of Onconetix's value that differs from its market value or its book value, called intrinsic value, which is Onconetix's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Onconetix's market value can be influenced by many factors that don't directly affect Onconetix's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Onconetix's value and its price as these two are different measures arrived at by different means. Investors typically determine if Onconetix is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Onconetix's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.